Towa Pharmaceutical
Basic Information
- Stock Code
- 4553
- Industry
- Pharmaceuticals
- Category Detail
- Biotechnology & Pharmaceuticals
- Prefecture
- Osaka Prefecture
- Establishment Year
- April 1957
- Listing Year
- July 1994
- Official Website
- https://www.towayakuhin.co.jp/
- TSE Information
- TSE Information
- Yahoo! Finance
- Yahoo! Finance
- Other Companies
- Fuso Pharma, Kissei, Fuji Pharma, Sawai GHD
Overview
Towa Pharmaceutical is a major generic drug specialist founded in 1957, with strengths in the cardiovascular field and primarily conducting business through direct sales.
Current Situation
Towa Pharmaceutical achieved consolidated sales of approximately ¥259.5 billion and operating profit of approximately ¥23.2 billion in the fiscal year ending March 2025, building a stable revenue base. It focuses mainly on the manufacturing and sales of generic drugs, with a direct sales system targeting private clinics as its strength. It is enhancing production capacity and technological capabilities through the operation of the new Yamagata factory and the establishment of a joint venture for soft capsule manufacturing in 2016. Centering on cardiovascular products, it is expanding its product portfolio and advancing development of Alzheimer's treatments using iPS cell drug discovery. It is also promoting sustainability activities in environment and health fields, and continuing strategic investments for stable growth and new product development toward 2030. Since 2020, it has focused on dementia prevention research, aiming to create new markets in food and supplements. It maintains a financial position that allows aggressive R&D investment due to solid operating cash flow.
Trivia
Interesting Facts
- Developed the orally disintegrating tablet 'RACTAB' that won the 2012 Good Design Award.
- Built the Yamagata new factory on the site of the former Kamiyama Racecourse.
- President Yoshitsugu Yoshida is affiliated with the shareholder Yoshida Office.
- Successfully raised awareness by featuring celebrities Chieko Baisho and Yuzuru Hanyu in CMs.
- Acquired naming rights for Kadoma Sports Center, naming it 'Towa Pharmaceutical RACTAB Dome'.
- Challenging dementia prevention through joint research with the National Cerebral and Cardiovascular Center.
- Established unique direct sales network strong in private clinic generics market.
- Possesses advanced formulation technology capable of manufacturing diverse generic forms.
- Succeeded in brand recognition as long-term sponsor of TV news programs.
- Contributing to regional revitalization with multiple labs and factories in local Osaka.
Hidden Connections
- Builds strong direct sales relationships with major customers (private clinics), contributing to sales strength.
- Joint research with National Cerebral and Cardiovascular Center strengthens ties with hospitals and medical institutions.
- JV establishment deepens technological diversity and competitiveness in pharmaceutical manufacturing.
- Popularity of TV CM talents greatly contributes to corporate brand recognition.
- Headquarters in Kadoma City, Osaka, contributing to formation of local medical industry cluster.
- Succeeding in differentiation through stable supply and quality amid intensifying generic price competition.
- Achieved expansion of generic market share for patent-expired drugs through formulation technology improvements.
- Built efficient system integrating manufacturing and R&D through collaboration with affiliates.
Future Outlook
Growth Drivers
- Creation of new markets in dementia prevention
- Stable increasing demand in generic drug market
- Strengthening of drug discovery using iPS cell technology
- Expansion of direct sales channels to domestic medical institutions
- Supply stabilization through production capacity enhancement
- Improved product competitiveness through diversification of formulation technology development
- Growth in pharmaceutical demand responding to aging society
- Market expansion from government generic drug promotion policies
- Building sustainable manufacturing systems compliant with environmental regulations
- Response to functional enhancement in supplement market
- Strengthening of region-focused services
- Gradual entry into global pharmaceutical markets
Strategic Goals
- Achieve over 40% domestic share in generic drugs
- Commercialization and revenue generation of iPS cell drug discovery business
- Top domestic brand for dementia prevention products
- 50% reduction in factory environmental impact
- Acquire 5 or more patents for new formulation technologies
- Strengthen nationwide direct sales rollout
- Achieve sales over ¥400 billion
- 20% ratio of generic sales in overseas markets
- 20 or more joint research projects with medical institutions annually
- Maintain employee retention rate over 90%
Business Segments
Product Supply to Hospitals and Medical Institutions
- Overview
- Segment providing stable supply of pharmaceuticals to medical institutions, centered on generic drugs.
- Competitiveness
- Advanced response to medical institutions through direct sales system
- Customers
-
- Hospitals
- Clinics
- Private practices
- Pharmacies
- Products
-
- Generic drug formulations
- Injections
- Ointments
- Oral tablets
Formulation Technology Provision & OEM Contract Manufacturing
- Overview
- Contract manufacturing and technology provision leveraging formulation development technology.
- Competitiveness
- Advanced formulation technology and new factory equipment
- Customers
-
- Domestic pharmaceutical companies
- Overseas pharmaceutical companies
- Research institutions
- Biotech ventures
- Products
-
- Capsule formulations
- Powder formulations
- Granule formulations
- Injection manufacturing
R&D Related Services
- Overview
- Provides advanced research services supporting pharmaceutical development.
- Competitiveness
- Expertise in iPS drug discovery technology
- Customers
-
- Pharmaceutical company labs
- Academic institutions
- Public research institutions
- Products
-
- Screening of new drug candidate compounds
- iPS cell drug discovery support
- Functional ingredient development
API Procurement & Logistics Services
- Overview
- Pharmaceutical raw material procurement and efficient logistics support.
- Competitiveness
- Visualization and optimization of procurement routes
- Customers
-
- Pharmaceutical companies
- Wholesalers
- Medical institutions
- Products
-
- Pharmaceutical APIs
- Intermediates
- Logistics management services
Competitive Advantage
Strengths
- High market share in generic drugs
- Customer-close system centered on direct sales
- Strong cardiovascular product portfolio
- Advanced formulation technology and new factory production capacity
- R&D capabilities and utilization of iPS cell drug discovery
- Aggressive investments backed by stable funding
- Medical institution network built on long-term trust and track record
- Secured diverse sales channels
- Brand value from Good Design Award-winning products
- Precise management of API procurement routes
Competitive Advantages
- Market penetration through direct sales to private clinics
- Production capacity with multiple in-house factories in Japan
- Pioneering in new drug development using iPS cell technology
- Specialization focused on cardiovascular diseases
- Aggressive entry into new areas like dementia prevention
- Prompt response to medical institutions and detailed customer service
- Supply system for multiple pharmaceutical forms (tablets, patches, capsules, etc.)
- Strong brand recognition and advertising rollout
- Abundant patents and technical know-how
- Strengthened management base through stable major shareholder system
Threats
- Intensifying price competition in generic drug market
- Market saturation risk from patent expirations of new drugs
- Impact of pharmaceutical regulatory changes and legal amendments
- Expansion of overseas generic companies
- Profit pressure from healthcare cost containment policies
- Uncertainty in R&D outcomes and investment recovery risk
- Supply chain disruptions from novel infectious diseases, etc.
- Raw material cost fluctuations due to exchange rate changes
- Changes in domestic medical demand due to population decline
- Intensifying technological development competition with rivals
Innovations
2020: Launch of Takixyphorin research for dementia prevention
- Overview
- Promoting development of dementia prevention foods and supplements in collaboration with the National Cerebral and Cardiovascular Center.
- Impact
- Building foundation for entry into functional food market
2023: Progress in final clinical trial for iPS cell-based Alzheimer treatment drug
- Overview
- New drug candidate using drug discovery technology advances to final trial stage for familial Alzheimer's.
- Impact
- Heightened expectations for new market acquisition
2022: Expansion of production capacity at Yamagata new factory
- Overview
- Introduced latest equipment to strengthen three-factory system in Japan, boosting production capacity.
- Impact
- Achieved annual production of 75 billion tablets
2021: Establishment of JV for pharmaceutical soft capsule manufacturing
- Overview
- Joint venture with Green Caps Pharmaceutical to advance new capsule manufacturing technology.
- Impact
- Promoting diversification of formulation technology
2024: Construction of API procurement route visualization system
- Overview
- Succeeded in stable raw material procurement and cost reduction through supply chain transparency.
- Impact
- Improved production efficiency and cost competitiveness
Sustainability
- Efforts to reduce environmental impact of manufacturing processes
- Collaboration with local communities for health promotion
- Social contribution through safe pharmaceutical provision
- Proper management of pharmaceutical waste
- Employee health and welfare enhancement programs